通过大肠杆菌外膜囊泡传递鼠疫耶尔森菌抗原可提高对鼠疫的防护能力。

IF 3.7 2区 生物学 Q2 MICROBIOLOGY
mSphere Pub Date : 2024-09-25 Epub Date: 2024-08-19 DOI:10.1128/msphere.00330-24
Zehui Tong, Xiangting Zhang, Xiao Guo, Gengshan Wu, Shiyang Cao, Yuan Zhang, Xiangze Meng, Tong Wang, Yiqian Wang, Yajun Song, Ruifu Yang, Zongmin Du
{"title":"通过大肠杆菌外膜囊泡传递鼠疫耶尔森菌抗原可提高对鼠疫的防护能力。","authors":"Zehui Tong, Xiangting Zhang, Xiao Guo, Gengshan Wu, Shiyang Cao, Yuan Zhang, Xiangze Meng, Tong Wang, Yiqian Wang, Yajun Song, Ruifu Yang, Zongmin Du","doi":"10.1128/msphere.00330-24","DOIUrl":null,"url":null,"abstract":"<p><p>Outer membrane vesicles (OMVs) from Gram-negative bacteria can be used as a vaccine platform to deliver heterologous antigens. Here, the major protective antigens of <i>Yersinia pestis,</i> F1 and LcrV, were fused either with the leader sequence or the transmembrane domain of the outer membrane protein A (OmpA), resulting in chimeric proteins OmpA-ls-F1V and OmpA<sub>46-159</sub>-F1V, respectively. We show that OmpA-ls-F1V and OmpA<sub>46-159</sub>-F1V can be successfully delivered into the lumen and membrane of the OMVs of <i>Escherichia coli,</i> respectively. Mutation of <i>ompA</i> but not <i>tolR</i> in <i>E. coli</i> enhanced the delivery efficiency of OmpA-ls-F1V into OMVs. The OmpA-ls-F1V protein comprises up to 20% of the total protein in OMVs derived from the <i>ompA</i> mutant (OMV<sub>dA</sub>-ALS-F1V), a proportion significantly higher than the 1% observed for OmpA<sub>46-159</sub>-F1V in OMVs produced by an <i>ompA</i> mutant that expresses OmpA46-159-F1V, referred to as OMV<sub>dA</sub>-LATM5-F1V. Intramuscular (<i>i.m</i>.) immunization of mice with OMV<sub>dA</sub>-ALS-F1V induced significantly higher levels of serum anti-LcrV and anti-F1 IgG, and provided higher efficacy in protection against subcutaneous (<i>s.c.</i>) <i>Y. pestis</i> infection compared to OMV<sub>dA</sub>-LATM5-F1V and the purified recombinant F1V (rF1V) protein adsorbed to aluminum hydroxide. The three-dose <i>i.m</i>. immunization with OMV<sub>dA</sub>-ALS-F1V, administered at 14-day intervals, provides complete protection to mice against <i>s.c.</i> infection with 130 LD<sub>50</sub> of <i>Y. pestis</i> 201 and conferred 80% against intranasal (<i>i.n</i>.) challenge with 11.4 LD<sub>50</sub> of <i>Y. pestis</i> 201. Taken together, our findings indicate that the engineered OMVs containing F1V fused with the leader sequence of OmpA provide significantly higher protection than rF1V against both <i>s.c</i>. and <i>i.n</i>. infection of <i>Y. pestis</i> and more balanced Th1/Th2 responses.IMPORTANCEThe two major protective antigens of <i>Y. pestis</i>, LcrV and F1, have demonstrated the ability to elicit systemic and local mucosal immune responses as subunit vaccines. However, these vaccines have failed to provide adequate protection against pneumonic plague in African green monkeys. Here, <i>Y. pestis</i> F1 and LcrV antigens were successfully incorporated into the lumen and the surface of the outer membrane vesicles (OMVs) of <i>E. coli</i> by fusion either with the leader sequence or the transmembrane domain of OmpA. We compared the humoral immune response elicited by these OMV formulations and their protective efficacy in mice against <i>Y. pestis</i>. Our results demonstrate that the plague OMV vaccine candidates can induce robust protective immunity against both <i>s.c</i>. and <i>i.n. Y. pestis</i> infections, surpassing the effectiveness of rF1V. In addition, immunization with OMVs generated a relatively balanced Th1/Th2 immune response compared to rF1V immunization. These findings underscore the potential of OMVs-based plague vaccines for further development.</p>","PeriodicalId":19052,"journal":{"name":"mSphere","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11423571/pdf/","citationCount":"0","resultStr":"{\"title\":\"Delivery of <i>Yersinia pestis</i> antigens via <i>Escherichia coli</i> outer membrane vesicles offered improved protection against plague.\",\"authors\":\"Zehui Tong, Xiangting Zhang, Xiao Guo, Gengshan Wu, Shiyang Cao, Yuan Zhang, Xiangze Meng, Tong Wang, Yiqian Wang, Yajun Song, Ruifu Yang, Zongmin Du\",\"doi\":\"10.1128/msphere.00330-24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Outer membrane vesicles (OMVs) from Gram-negative bacteria can be used as a vaccine platform to deliver heterologous antigens. Here, the major protective antigens of <i>Yersinia pestis,</i> F1 and LcrV, were fused either with the leader sequence or the transmembrane domain of the outer membrane protein A (OmpA), resulting in chimeric proteins OmpA-ls-F1V and OmpA<sub>46-159</sub>-F1V, respectively. We show that OmpA-ls-F1V and OmpA<sub>46-159</sub>-F1V can be successfully delivered into the lumen and membrane of the OMVs of <i>Escherichia coli,</i> respectively. Mutation of <i>ompA</i> but not <i>tolR</i> in <i>E. coli</i> enhanced the delivery efficiency of OmpA-ls-F1V into OMVs. The OmpA-ls-F1V protein comprises up to 20% of the total protein in OMVs derived from the <i>ompA</i> mutant (OMV<sub>dA</sub>-ALS-F1V), a proportion significantly higher than the 1% observed for OmpA<sub>46-159</sub>-F1V in OMVs produced by an <i>ompA</i> mutant that expresses OmpA46-159-F1V, referred to as OMV<sub>dA</sub>-LATM5-F1V. Intramuscular (<i>i.m</i>.) immunization of mice with OMV<sub>dA</sub>-ALS-F1V induced significantly higher levels of serum anti-LcrV and anti-F1 IgG, and provided higher efficacy in protection against subcutaneous (<i>s.c.</i>) <i>Y. pestis</i> infection compared to OMV<sub>dA</sub>-LATM5-F1V and the purified recombinant F1V (rF1V) protein adsorbed to aluminum hydroxide. The three-dose <i>i.m</i>. immunization with OMV<sub>dA</sub>-ALS-F1V, administered at 14-day intervals, provides complete protection to mice against <i>s.c.</i> infection with 130 LD<sub>50</sub> of <i>Y. pestis</i> 201 and conferred 80% against intranasal (<i>i.n</i>.) challenge with 11.4 LD<sub>50</sub> of <i>Y. pestis</i> 201. Taken together, our findings indicate that the engineered OMVs containing F1V fused with the leader sequence of OmpA provide significantly higher protection than rF1V against both <i>s.c</i>. and <i>i.n</i>. infection of <i>Y. pestis</i> and more balanced Th1/Th2 responses.IMPORTANCEThe two major protective antigens of <i>Y. pestis</i>, LcrV and F1, have demonstrated the ability to elicit systemic and local mucosal immune responses as subunit vaccines. However, these vaccines have failed to provide adequate protection against pneumonic plague in African green monkeys. Here, <i>Y. pestis</i> F1 and LcrV antigens were successfully incorporated into the lumen and the surface of the outer membrane vesicles (OMVs) of <i>E. coli</i> by fusion either with the leader sequence or the transmembrane domain of OmpA. We compared the humoral immune response elicited by these OMV formulations and their protective efficacy in mice against <i>Y. pestis</i>. Our results demonstrate that the plague OMV vaccine candidates can induce robust protective immunity against both <i>s.c</i>. and <i>i.n. Y. pestis</i> infections, surpassing the effectiveness of rF1V. In addition, immunization with OMVs generated a relatively balanced Th1/Th2 immune response compared to rF1V immunization. These findings underscore the potential of OMVs-based plague vaccines for further development.</p>\",\"PeriodicalId\":19052,\"journal\":{\"name\":\"mSphere\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11423571/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"mSphere\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1128/msphere.00330-24\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"mSphere","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1128/msphere.00330-24","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

革兰氏阴性细菌的外膜囊泡 (OMV) 可用作传递异源抗原的疫苗平台。在这里,鼠疫耶尔森菌的主要保护性抗原 F1 和 LcrV 与外膜蛋白 A(OmpA)的前导序列或跨膜结构域融合,分别产生了嵌合蛋白 OmpA-ls-F1V 和 OmpA46-159-F1V。我们的研究表明,OmpA-ls-F1V 和 OmpA46-159-F1V 可分别成功地输送到大肠杆菌外膜蛋白的腔和膜中。大肠杆菌中otlR的突变增强了OmpA-ls-F1V向OMV的递送效率。在由 OmpA 突变体(OMVdA-ALS-F1V)产生的 OMV 中,OmpA-ls-F1V 蛋白占总蛋白的 20%,这一比例明显高于在由表达 OmpA46-159-F1V 的 OmpA 突变体(OMVdA-LATM5-F1V)产生的 OMV 中观察到的 OmpA46-159-F1V 的 1%。与OMVdA-LATM5-F1V和吸附在氢氧化铝上的纯化重组F1V(rF1V)蛋白相比,用OMVdA-ALS-F1V对小鼠进行肌内(i.m.)免疫可诱导明显更高水平的血清抗LcrV和抗F1 IgG,并提供更高的皮下(s.c.)Y. pestis感染保护效力。OMVdA-ALS-F1V的三剂量i.m.免疫(每隔14天注射一次)为小鼠提供了完全的保护,使其免受Y. pestis 201 130 LD50的静脉注射感染,并对Y. pestis 201 11.4 LD50的鼻内(i.n.)挑战提供了80%的保护。总之,我们的研究结果表明,与rF1V相比,含有与OmpA前导序列融合的F1V的工程OMV在鼠疫Y.c.和i.n.感染时可提供明显更高的保护性,并可产生更平衡的Th1/Th2反应。然而,这些疫苗未能为非洲绿猴提供足够的肺鼠疫保护。在这里,通过与 OmpA 的前导序列或跨膜结构域融合,Y. pestis F1 和 LcrV 抗原被成功地结合到大肠杆菌的腔体和外膜囊泡 (OMV) 表面。我们比较了这些 OMV 制剂引起的体液免疫反应及其对小鼠鼠疫 Y. pestis 的保护效力。我们的研究结果表明,鼠疫 OMV 候选疫苗可诱导针对鼠疫 Y. pestis s.c. 和 i.n. 感染的强大保护性免疫,其有效性超过了 rF1V。此外,与rF1V免疫相比,OMV免疫可产生相对平衡的Th1/Th2免疫反应。这些发现强调了基于 OMVs 的鼠疫疫苗的进一步开发潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Delivery of Yersinia pestis antigens via Escherichia coli outer membrane vesicles offered improved protection against plague.

Outer membrane vesicles (OMVs) from Gram-negative bacteria can be used as a vaccine platform to deliver heterologous antigens. Here, the major protective antigens of Yersinia pestis, F1 and LcrV, were fused either with the leader sequence or the transmembrane domain of the outer membrane protein A (OmpA), resulting in chimeric proteins OmpA-ls-F1V and OmpA46-159-F1V, respectively. We show that OmpA-ls-F1V and OmpA46-159-F1V can be successfully delivered into the lumen and membrane of the OMVs of Escherichia coli, respectively. Mutation of ompA but not tolR in E. coli enhanced the delivery efficiency of OmpA-ls-F1V into OMVs. The OmpA-ls-F1V protein comprises up to 20% of the total protein in OMVs derived from the ompA mutant (OMVdA-ALS-F1V), a proportion significantly higher than the 1% observed for OmpA46-159-F1V in OMVs produced by an ompA mutant that expresses OmpA46-159-F1V, referred to as OMVdA-LATM5-F1V. Intramuscular (i.m.) immunization of mice with OMVdA-ALS-F1V induced significantly higher levels of serum anti-LcrV and anti-F1 IgG, and provided higher efficacy in protection against subcutaneous (s.c.) Y. pestis infection compared to OMVdA-LATM5-F1V and the purified recombinant F1V (rF1V) protein adsorbed to aluminum hydroxide. The three-dose i.m. immunization with OMVdA-ALS-F1V, administered at 14-day intervals, provides complete protection to mice against s.c. infection with 130 LD50 of Y. pestis 201 and conferred 80% against intranasal (i.n.) challenge with 11.4 LD50 of Y. pestis 201. Taken together, our findings indicate that the engineered OMVs containing F1V fused with the leader sequence of OmpA provide significantly higher protection than rF1V against both s.c. and i.n. infection of Y. pestis and more balanced Th1/Th2 responses.IMPORTANCEThe two major protective antigens of Y. pestis, LcrV and F1, have demonstrated the ability to elicit systemic and local mucosal immune responses as subunit vaccines. However, these vaccines have failed to provide adequate protection against pneumonic plague in African green monkeys. Here, Y. pestis F1 and LcrV antigens were successfully incorporated into the lumen and the surface of the outer membrane vesicles (OMVs) of E. coli by fusion either with the leader sequence or the transmembrane domain of OmpA. We compared the humoral immune response elicited by these OMV formulations and their protective efficacy in mice against Y. pestis. Our results demonstrate that the plague OMV vaccine candidates can induce robust protective immunity against both s.c. and i.n. Y. pestis infections, surpassing the effectiveness of rF1V. In addition, immunization with OMVs generated a relatively balanced Th1/Th2 immune response compared to rF1V immunization. These findings underscore the potential of OMVs-based plague vaccines for further development.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
mSphere
mSphere Immunology and Microbiology-Microbiology
CiteScore
8.50
自引率
2.10%
发文量
192
审稿时长
11 weeks
期刊介绍: mSphere™ is a multi-disciplinary open-access journal that will focus on rapid publication of fundamental contributions to our understanding of microbiology. Its scope will reflect the immense range of fields within the microbial sciences, creating new opportunities for researchers to share findings that are transforming our understanding of human health and disease, ecosystems, neuroscience, agriculture, energy production, climate change, evolution, biogeochemical cycling, and food and drug production. Submissions will be encouraged of all high-quality work that makes fundamental contributions to our understanding of microbiology. mSphere™ will provide streamlined decisions, while carrying on ASM''s tradition for rigorous peer review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信